The EU’s AI Act will reshape how pharma markets, personalises, and measures. This panel explore pharma frameworks, and how to stay compliant without holding back innovation.
Outcome: Leave a strong understanding of how AI solutions may violate the EU AI Act. Critical for those tasked with rolling out global initiatives in EU markets.
Pharma’s next edge won’t come from the biggest model, but the boldest instincts. Learn how to spot moments of asymmetric opportunity - when to trust data, and when to break pattern. You’ll leave knowing how AI with timing is your new competitive advantage.
